drugset / Trial / NCT07177716
Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a multicenter, randomized, open-label Phase II/III clinical study, aiming to evaluate the efficacy and safety of LB1410 in combination with lenvatinib (whether in combination with LB4330）versus the chemotherapy regimen selected by the investigators for patients with advanced recurrent/metastatic cervical cancer.
Timeline
- Start
- 2025-10
- Primary completion
- 2028-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LB1410 | Unknown | — | Intravenous |
| Subject | LB4330 | Protein / enzyme biologic | — | Intravenous |
| Subject | Lenvatinib | Small molecule | — | Oral |